Lepzacitinib

Modify Date: 2024-01-12 20:15:27

Lepzacitinib structure	Common Name	Lepzacitinib
	CAS Number	2321488-47-3	Molecular Weight	355.39
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₈H₂₁N₅O₃	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Lepzacitinib

Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases[1].

Name	Lepzacitinib

Description	Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases[1].
Related Catalog	Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK Research Areas >> Inflammation/Immunology
Target	JAK 1/3[1]
References	[1]. Anderson, et al. Preparation of substituted pyrrolopyridine compounds as JAK inhibitors. World Intellectual Property Organization, WO2019090158 A1 2019-05-09.

Molecular Formula	C₁₈H₂₁N₅O₃
Molecular Weight	355.39

Dichloromethane
CAS#:75-09-2

Polyacrylic acid
CAS#:9003-01-4

sodium carbonate
CAS#:497-19-8

Silicon dioxide
CAS#:7631-86-9

Triethanolamine
CAS#:102-71-6

Demeton
CAS#:126-75-0

Water
CAS#:7732-18-5

4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9

Diclofenac sodium
CAS#:15307-79-6

Budesonide
CAS#:51372-29-3

Lepzacitinib

Use of Lepzacitinib

Names

Lepzacitinib Biological Activity

Chemical & Physical Properties